ABNXP Stock Overview
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.73 |
| 52 Week High | €1.73 |
| 52 Week Low | €1.73 |
| Beta | 0.28 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 169.36% |
| 5 Year Change | -5.87% |
| Change since IPO | -86.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABNXP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | n/a | -18.3% | 8.0% |
Return vs Industry: Insufficient data to determine how ABNXP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ABNXP performed against the UK Market.
Price Volatility
| ABNXP volatility | |
|---|---|
| ABNXP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ABNXP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABNXP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 62 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France.
ABIONYX Pharma SA Fundamentals Summary
| ABNXP fundamental statistics | |
|---|---|
| Market cap | €62.09m |
| Earnings (TTM) | -€5.83m |
| Revenue (TTM) | €3.28m |
18.9x
P/S Ratio-10.7x
P/E RatioIs ABNXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABNXP income statement (TTM) | |
|---|---|
| Revenue | €3.28m |
| Cost of Revenue | €2.95m |
| Gross Profit | €324.00k |
| Other Expenses | €6.15m |
| Earnings | -€5.83m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Apr 27, 2023
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 9.88% |
| Net Profit Margin | -177.73% |
| Debt/Equity Ratio | 23.6% |
How did ABNXP perform over the long term?
See historical performance and comparison